Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-1305 first-in-human dose-escalation and expansion study in advanced solid tumors
NL-OMON54504Phase 2Recruiting
- Sponsor
- Faron Pharmaceuticals
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bexmarilimab in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma (CCA), colorectal adenocarcinoma, sponsored by Faron Pharmaceuticals. Started Nov 2019; status: recruiting.
02
Drugs
bexmarilimab
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)gallbladder cancercholangiocarcinoma (CCA)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON54504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54504.